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Capsule summary 64 
We fully characterise the first reported functional deficiency of complement factor D in a 65 
patient. The structural analysis yielded a novel approach by which this key enzyme could be 66 
inhibited to treat inflammatory diseases.  67 
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Abbreviations used 73 
AMD: age-related macular degeneration  74 
AP: alternative complement pathway  75 
AP50: alternative pathway haemolytic activity  76 
CH50: classical pathway haemolytic activity  77 
FB: complement factor B  78 
FD: complement factor D  79 
MD: molecular dynamics  80 
WT: wild-type  81 
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To the Editor: 82 
We investigated an alternative complement pathway (AP) deficiency in a patient with absent 83 
alternative pathway haemolytic activity (AP50) but normal classical pathway haemolytic 84 
activity recovering from invasive meningococcal infection (for patient and sibling details, see 85 
Appendix A in this article’s Online Repository). Serum reconstitution with proximal AP 86 
components suggested a Factor D (FD) deficiency (Fig 1A). Sanger sequencing of CFD 87 
identified a rare homozygous missense mutation (c.602G>C) in exon 4 in the patient (II-1) 88 
and sibling (II-2), resulting in an arginine to proline substitution (p. R176P) (see Fig E1, A, in 89 
this article’s Online Repository). This genotype co-segregated with an AP50-null phenotype, 90 
as the parents, both heterozygotes, had normal AP50 (Fig 1B). In contrast to previous 91 
confirmed FD deficiencies,1-3 all members of the pedigree had normal levels of circulating 92 
FD, as corroborated by western blot (see Fig E1, B). Meanwhile, identical circular dichroism 93 
spectra and melting curves of recombinant wild-type (WT) and R176P FD precluded gross 94 
changes in FD structure or stability, suggesting a functional deficiency (Fig 1C and see Fig 95 
E1, C). We assessed the cleavage of C3b-bound Factor B (FB) by recombinant WT and 96 
mutant FD (R176P, R176A, R176Q). WT FD could cleave C3b-bound FB to produce 97 
fragments Bb and Ba. Conversely, R176P FD demonstrated diminished in vitro catalytic 98 
activity at all concentrations, and had negligible activity at physiological concentration (0.04 99 
µM) (Fig 1D and see E1, D). Reconstitution of FD-depleted serum with R176P FD also 100 
demonstrated impaired AP mediated haemolysis (see Fig E1, E). 101 
 102 
FD’s serine protease activity depends on obligatory binding to the C3bB complex via four 103 
exosite loops (residues 132-135, 155-159, 173-176, 203-209). This leads to rearrangement of 104 
the self-inhibitory loop (199-202), allowing realignment of His41 and Asp89 with Ser183 to 105 
form the active catalytic triad (see Fig E2, A and B, in this article’s Online Repository).4, 5 106 
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Mutation R176P lies outside the active site, within one of the FB-binding exosite loops. We 107 
used molecular dynamics (MD) stimulations to study how the R176P mutation affects the FD 108 
protein fold (see Fig E2, C). In mutant FD, we observed a rearrangement of the exosite loop 109 
155-161 within 50 ns of simulation (Fig 2A). This was unexpected because loop 155-161 was 110 
not in direct contact with residue 176. Average structures generated from the final 50 ns of 111 
simulation for WT and mutant FD (R176P and R176A) demonstrated that key FB-binding 112 
residues Asp161 and Arg157 were shifted by 4.3 Å and 1.9 Å respectively (Cα average 113 
position) (Fig 2B). Superimposing these MD average structures onto the crystal structure of 114 
the C3bB-D complex revealed that Asp161 and Arg157 assumed a conformation that no 115 
longer supported binding due to loss of shape and charge complementarity to the FB surface 116 
(Fig 2C). The other three exosite loops retained their binding-competent conformations. After 117 
assuming the new conformation, exosite loop 155-161 demonstrated higher conformational 118 
mobility (root mean square fluctuation) relative to WT (Fig E2, D and E). In contrast, the 119 
mobility of loops containing catalytic residues His41 and Asp89 decreased in the mutants. 120 
Using the distance between His41 and Ser183 during MD simulations as a proxy for the 121 
active site conformation, we observed that WT could sample the short distance necessary for 122 
a catalytically active conformation (Fig 2D). Conversely, in both mutant simulations, the 123 
distance remained larger, consistent with His41 pointing away from the active site. Therefore, 124 
in addition to disruption of key FB-binding residues, mutations R176P and R176A appear to 125 
stabilise the self-inhibited conformation of free FD.  126 
 127 
To assess the binding of FD to C3bB, we used surface plasmon resonance. Co-injection of 128 
catalytically inactive FD (WT/S183A) with FB demonstrated a dose-dependent increase in 129 
binding to C3b and complex formation (Fig 2E). In contrast, R176P/S183A FD lacked any 130 
detectable binding (Fig 2F). Consistent with the stochastic transitions of free WT FD to the 131 
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active conformation observed in the MD simulation, FD has a low level of esterolytic activity 132 
towards a small synthetic substrate, Z-Lys-SBzl (Fig 2D). Surprisingly, R176P FD 133 
demonstrated a loss of esterolytic activity similar to the active site mutant, S183A (see Fig 134 
2G).  135 
 136 
Deficiency of properdin, the most common AP deficiency, can result from absent (type I), 137 
low (type II) or normal but non-functioning (type III) protein levels (for reference, see 138 
Reference E10 in this article’s Online Repository). Meanwhile, previously confirmed 139 
deficiencies of activating complement serine proteases have all resulted in low or absent gene 140 
product. We have identified a unique deficiency: R176P FD is fully expressed and stable, but 141 
enzymatically inert, constituting a functional or Type III deficiency. Recent preclinical 142 
evidence6 that FD deficient mice are susceptible to diabetes prompted metabolic assessment 143 
in the FD deficient patients. No abnormality was detected (for details, see Appendix B, Fig 144 
E3 and Table E1 in this article’s Online Repository). 145 
 146 
Over-activation of AP is implicated in numerous inflammatory disorders, including age-147 
related macular degeneration (AMD). Therefore, blockade of the AP by targeting the rate-148 
limiting enzyme, FD, is an attractive approach to controlling disease progression. An anti-FD 149 
Fab fragment targeting the two distal exosite loops has shown some benefit in phase II 150 
clinical trials for treatment of dry AMD.7 In vitro studies indicate that it inhibits binding to 151 
the C3bB complex but increases esterolytic activity towards small-molecule substrates.8 This 152 
may result in unwanted clinical effects due to non-specific activity or limit its efficacy in 153 
vivo. In the case of R176P FD, both FB-binding and esterolytic activity are abrogated 154 
through exosite hindrance and stabilisation of the self-inhibited state. Loop 173-176 is thus a 155 
promising target for allosteric inhibitors of FD that stabilise the inhibitory loop in addition to 156 
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binding-blockade.  A structure-based design approach to targeting FD has recently succeeded 157 
in identifying candidate FD inhibitors where high-throughput screens had failed,9 158 
highlighting the benefits of integrating structural information into candidate drug screens. 159 
Comprehensive definition of the structural and molecular determinants of in vivo FD activity 160 
is critical for this. This study of the R176P mutation demonstrates how in-depth mechanistic 161 
analysis of rare complement deficiencies can deliver such insight validated clinically by in 162 
vivo human evidence of AP blockade. 163 
 164 
Our acknowledgements can be found in this article’s Online Repository. 165 
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Figure legends 234 
Figure 1: Assessing the contribution of mutation R176P to AP dysfunction. 235 
(A) AP50 assay assessing patient serum supplemented with properdin (P), factor B (FB) or 236 
factor D (FD).  237 
(B) The immediate family pedigree of the patient with the CFD genotype, serum AP50 and 238 
serum FD concentrations displayed. D, WT allele. d, mutant allele (c.602G>C).  239 
(C) Thermal shift assay of WT and R176P FD.   240 
(D) Serial dilutions of recombinant WT or R176P FD were incubated with C3b and FB. The 241 
SDS-PAGE gel, stained with AcquaStain, shows the individual proteins and resultant 242 
products.  243 
 244 
Figure 2: Defining the effects of the R176P mutation on FD function. 245 
(A and B) FB-binding exosite loop 155-167 assumes a new conformation in mutant FD 246 
simulation. Arrows highlight average Cα position shifts of two residues that bind C3bB in the 247 
R176P FD simulation. 248 
(C) Loss of shape complementarity at the FD-C3bB interface. FD exosite loops from 249 
published co-crystal structures (white, PDB ID: 2XWB) overlaid with the simulated loops of 250 
WT and mutant FD.  251 
(D) Distance sampled between the active site Nε2 nitrogen of His41 and Oγ of Ser183 during 252 
each simulation. The shorter distance is necessary for catalytic activity. 253 
(E and F) SPR binding measurement of enzymatically inactive recombinant FD 254 
(R176P/S183A or WT/S183A) to C3bB complex.  255 
(G) Steady state kinetics for Z-Lys-SBzl cleavage by WT, R176P, R176A and catalytically 256 
inactive control S183A FD.  257 
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APPENDIX A 1 
Patient details 2 
A 19-year-old, South Asian female presented with a 24-hour history of high fever, rigors, 3 
delirium and diarrhoea. On clinical examination, she was febrile with a purpuric rash and a 4 
reduced level of consciousness (Glasgow Coma scale score: 9/15). Intravenous antibiotic 5 
therapy was initiated for provisionally diagnosed meningococcal septicaemia. She was 6 
intubated and transferred to the intensive care unit where she developed disseminated 7 
intravascular coagulation, for which she received treatment.  Results from blood cultures 8 
drawn at the time of admission confirmed an infection with Neisseria meningitides serogroup 9 
Y.  Her clinical condition improved with intensive care support and antimicrobial therapy. 10 
She was discharged after two weeks with minimal sequelae including bilateral leg scarring, a 11 
sacral pressure sore and mild bilateral hearing loss.  12 
  13 
At the age of 5 years, she had received bilateral tympanostomy tubes for recurrent ear 14 
infections and otitis media with effusion but had no other unusual infections as a child. She 15 
received the full course of childhood vaccinations as per the national immunisation schedule.  16 
  17 
On screening for immunodeficiency, laboratory measurement demonstrated a normal full 18 
blood count with normal counts of lymphoid cells. The titres of C3, C4, mannose-binding 19 
lectin and C1q were within normal range, but there was undetectable alternative 20 
pathwayhaemolytic activity (AP50) in conjunction with normal classical pathway haemolytic 21 
activity. In view of her complement deficiency, she was prescribed lifelong 22 
phenoxymethylpenicillin as antimicrobial prophylaxis. She was also vaccinated for 23 
meningitis ACWY, meningitis C, pneumococcus and haemophilus influenza B to which she 24 
developed high antibody titre responses.  25 
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 26 
Her sole sibling, a younger male, who was homozygous for the same mutation, leading to an 27 
identical pattern on immunodeficiency screening, was healthy at assessment. He reported no 28 
excess of infections in the past. Of note, he reported having been treated empirically for 29 
suspected meningitis, aged 11, whilst travelling in Mauritius from which he recovered with 30 
no sequalae after a standard course of antibiotics.  31 
 32 
APPENDIX B 33 
Functional Factor D deficiency does not result in impaired oral glucose tolerance 34 
Recent pre-clinical evidenceE1 that FD regulates insulin secretion prompted metabolic 35 
assessment of the patient and her sibling. They had a BMI of 19.3 kg/m2 and 23.1 kg/m2, 36 
respectively. Fasting venous plasma glucose (5.2-5.4 mmol/L) and insulin (29-39 pmol/L) 37 
levels were normal in both subjects (Fig E3). Similarly, plasma glucose excursions were 38 
normal in response to an oral glucose (75g) challenge. At 120 minutes following glucose 39 
administration, glucose levels remained normal (4.0 mmol/L). Furthermore, circulating 40 
concentrations of leptin and adiponectin, adipokines which regulate insulin sensitivity, were 41 
normal, as were fasting lipid profiles in both subjects. Thus, glucose homeostasis is not 42 
impaired in the context of genetic, and therefore lifelong, FD deficiency.  43 
 44 
These results are consistent with the finding that FD knock-out mice developed impaired 45 
glucose tolerance only on a long-term diabetogenic diet. This suggests that FD may 46 
contribute little to glucose homeostasis in the absence of prolonged metabolic stress. 47 
Alternatively, the role of FD in glucose homeostasis could be independent of binding to 48 
C3bB or independent of its serine protease activity and, by extension, independent of its 49 
downstream effects on the complement cascade. While congenital deficiency of FD alone 50 
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may not lead to insulin insufficiency, Lo et al.’s findings warrant observation of oral glucose 51 
tolerance in such FD deficient patients under extreme metabolic stress and at older age. 52 
Further research will be required to understand the role of FD in glucose homeostasis and 53 
FD-deficient family pedigrees offer a useful clinical insight to this question.   54 
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METHODS 55 
Informed consent statement 56 
All study participants gave their informed consent as appropriate under approved protocols 57 
from local institutional review boards. The research was conducted at University College 58 
London and the University of Cambridge under approved protocols (#04/Q0501/119 for 59 
affected individuals, #07/H0720/182 for family members). 60 
 61 
Alternative pathway haemolytic activity measurement 62 
AP100 RC003.1 Kit (Binding Site) agar-chicken erythrocyte plates were prepared according 63 
to the manufacturer’s instructions, with kit control and calibration solutions added. 5µl 64 
aliquots of test serum were added to individual wells on the plates over ice. The loaded plates 65 
were then stored at 4°C for 18 hours to allow radial diffusion of serum components, followed 66 
by incubation at 37°C for 90 minutes to develop zones of lysis. The plates were then digitally 67 
scanned at high-resolution, and the diameters of zones of lysis were measured using ImageJ 68 
1.x computer software. Representative plates were selected for figures. The diameter of lysis 69 
correlates with alternative pathway activity (AP50) and is expressed out of 100% relative to 70 
kit control. Purified human Factor D (FD), Factor B and properdin for reconstitution assays 71 
were purchased from Complement Tech, Inc.  72 
  73 
Sanger sequencing 74 
Genomic DNA was isolated from blood samples with QIAamp Kits (QIAGEN). The CFD 75 
gene polymerase chain reaction was performed with primers annealing to intron sequences 76 
close to each exon as described previouslyE2. Specifically, regarding the R176P mutation, a 77 
258-bp genomic fragment comprising exon 4 was amplified by PCR with the primers 5'-78 
CTGGGGCATAGTCAACCAC-3' and 5'-TGGGCCCTGTTCCTACTTG-3'. The cDNA 79 
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numbering for the CFD variant identified is based on transcript NCBI Ref Seq accession no. 80 
NM_001928/Ensembl accession no. ENST00000327726.6, beginning at the ATG start 81 
codon. The genomic coordinates refer to the GRCh37 genome build. 82 
 83 
Western blot analysis 84 
Pooled control and the patient serum were diluted to 1:40 in tris-buffered saline and resolved 85 
by SDS-PAGE on NuPAGE 4-12% Bis-Tris Gels, then blotted to nitrocellulose membranes. 86 
FD was detected using goat anti-human FD (AF1824; R&D) and donkey anti-goat-IgG 87 
IRDye 680CW (LI-COR Biosciences, Lincoln, NE, USA) secondary antibodies. The 88 
membranes were imaged using the Odyssey Infrared Imaging System (LI-COR Biosciences, 89 
Nebraska, USA) 90 
  91 
Recombinant CFD expression and purification 92 
Lentiviral transfer plasmid, envelope plasmid (pMD2.G; gift from Didier Trono; AddGene 93 
plasmid #12260) and packaging plasmid (psPAX2; AddGene; gift from Didier Trono; 94 
AddGene plasmid #12259) were used to transfect HEK293T cells to produce lentiviral 95 
particles. The transfer vector (modified pLenti-CMV-GFP-Puro; gift of Eric Campeau – 96 
Addgene 17448) included human FD cDNA (WT, R176P, R176A, S183A) with C-terminus 97 
hexahistidine tag upstream of an IRES-Thy1.1 and a puromycin resistance gene (PuroR). 98 
Transfection was carried out using Lipofectamine 3000 and, after 24hrs, the media containing 99 
the lentiviral particles was used immediately to stably transduce newly plated HEK293T 100 
cells. After puromycin selection, stably transduced 293T cells were incubated with FreeStyle 101 
media (Gibco) supplemented with 6X Glutamax and 2mM valproic acid. After 7-14 days, 102 
secreted recombinant CFD was purified from this media using cobalt immobilised metal 103 
affinity chromatography. CFD was eluted in 150mM imidazole in PBS and buffer exchanged 104 
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by centrifugal concentration (Vivaspin® 20; 10,000Da pore size; Sartorius). Purity of the 105 
sample was confirmed on SDS-PAGE and mass spectrometry.  106 
  107 
Measuring in vitro catalytic activity of recombinant FD 108 
Purified human C3b and FB were purchased from Complement Technology, Inc. 109 
Recombinant WT, R176P or R176A FD were mixed in varying concentrations (1.0 µM, 0.2 110 
µM, 0.04 µM) with C3b (1.0 µM) and FB (1.0 µM) in veronal buffer (Lonza) with 10 mM 111 
MgCl2 to a final volume of 20 µL. Reaction tubes were incubated for 10 minutes at 37°C 112 
before the addition of sample loading buffer (NuPAGE® LDS Sample Buffer) to terminate 113 
the reaction. The samples were then heated to 70°C for 10 minutes and resolved by SDS-114 
PAGE on a Novex NuPAGE 4-12% Bis-Tris Gel. The gels were developed overnight with 115 
AcquaStain (Bulldog Bio), washed for 1 hour with distilled water, dried and digitally scanned 116 
at high-resolution. Analysis of percentage cleavage of FB was calculated by densitometry 117 
analysis using ImageJ 1.x computer software. Statistical comparisons between WT and 118 
R176P FD activity were performed at each concentration, from 4 independent experiments 119 
using the Kruskall-Wallis non-parametric t-test. 120 
  121 
Circular dichroism spectroscopy and thermal shift assay 122 
WT and R176P catalytically inactive (S183A) proteins were purified by size exclusion 123 
chromatography in chloride-free 0.1M sodium phosphate pH 7.0, diluted to a concentration 124 
of 2 mg/mL (72.4 µM), and loaded into a 0.1 mm quartz sample cell. Circular dichroism 125 
spectra were recorded at 20°C on a Jasco J-810 spectropolarimeter equipped with a Jasco 126 
PTC-348WI temperature controller. Spectra were acquired from 190-260 nm with 0.1 nm 127 
resolution and 1 nm bandwidth. Final spectra are the sum of 20 scans acquired at 50 128 
nm/minute. Thermal shift assay. 2 µg of protein was mixed with SYPRO Orange in PBS 129 
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with 25mM HEPES and fluorescence data acquired on a ViiA 7 real-time PCR system with 130 
thermal denaturation over increasing temperatures observed using 1°C intervals. 131 
 132 
Molecular dynamics (MD) simulation of mutant FD 133 
Starting models were derived from crystal structures of S183A FD (PDB ID 2XW9, 1.2 Å 134 
resolution) reported previously.E3 The catalytic residue was reverted to serine during the MD 135 
setup. CootE4 was used to place the Pro176 side chain in the Arg176 experimental density 136 
while minimizing clashes with surrounding atoms and aiming to achieve a favourable initial 137 
geometry. The resulting structures were further adjusted in UCSF Chimera.E5 The 138 
GROMACS packageE6 was used to set up and run MD simulations. The AMBER99SB-ILDN 139 
force fieldE7 and TIP3P water model were used and the structures placed in dodecahedral 140 
boxes with 10 Å padding and surrounded with solvent including water and 150 mM NaCl. 141 
Following steepest gradient energy minimization, a modified Berendsen thermostat (two 142 
groups, time constant 0.1 ps, temperature 310 K) followed by a Berendsen barostat (isotropic, 143 
coupling constant 0.5 ps, reference pressure 1 bar) were coupled to the system over 100 ps. 144 
100 ns runs of unrestrained MD trajectories were produced. Following removal of periodic 145 
boundary condition artefacts, MD runs were visualised and analysed in Chimera and bulk 146 
statistics extracted using GROMACS analysis routines. 147 
 148 
Surface plasmon resonance 149 
Binding experiments were carried out based on established protocol using a Biacore T200 150 
instrument.E8 FB and FD were buffer exchanged by gel filtration into veronal buffer with 151 
10mM MgCl2. C3b was immobilised on the CM5 chip by amine coupling to achieve 8000 152 
resonance units. A dual injection programme was designed where 0.1 µM or 1 µM FB was 153 
injected at a flow rate of 30uL/min for 3 minutes, followed by a second injection of a mix of 154 
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0.1 µM or 1 µM FB and FD at 30uL/min for 4 minutes. After 5 minutes for dissociation, the 155 
chip was regenerated by three 5-minute washes in 40mM acetate + 3M NaCl (pH 5.5). The 156 
chip was re-equilibrated in assay buffer for 5 minutes. Catalytically inactive FD (S183A) or 157 
double mutant R176P/S183A were used to emulate the binding response of wild-type or 158 
R176P respectively while preventing cleavage of FB and subsequent dissociation of the 159 
complex. 160 
  161 
Esterolytic activity of FD 162 
Z-Lys-SBzl was purchased from Sigma-Aldrich in powder form and reconstituted to 100 mM 163 
in 70% DMSO. The assay buffer consisted of 50 mM HEPES (pH7.5), 220mM NaCl and 2 164 
mM of Ellman's reagent (5,5-dithio-bis-(2-nitrobenzoic acid) [DTNB]; Sigma-Aldrich). Each 165 
reaction mixture contained FD (80nM), variable Z-Lys-SBzl concentrations (0.2-3.2 mM) 166 
and 8% v/v of DMSO in a final volume of 200 µl. Solutions were pre-warmed to 37°C before 167 
addition of substrate to initiate the reaction. Hydrolysis of Z-lys-SBzl was measured using 168 
CLARIOstar FS microplate reader through equimolar formation of chromophore 2-nitro-5-169 
thiobenzoate at 405 nm every 30 seconds for 90 minutes (ε = 13,600 M-1cm-1). The rate of 170 
hydrolysis was determined from linear slopes of the reaction curves. Reaction velocities, 171 
expressed in apparent turnover values were plotted against substrate concentration. 172 
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Table E1 173 
Analyte Proband Sibling 
Leptin (ng/ml) 10.6 11.3 
Adiponectin (µg/ml) 9.7 6.5 
NEFA (µmol/L) 391 212 
Cholesterol (mmol/L) 4.2 4 
HDL (mmol/L) 1.53 1.26 
LDL (mmol/L) 2.3 2.3 
Triglycerides (mmol/L) 0.8 0.9 
HbA1c (mmol/mol) 36 35 
 174 
NEFA, non-esterified fatty acids. HDL, high-density lipoprotein. LDL, low-density 175 
lipoprotein.  176 
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Figure legends 209 
Figure E1: Mutation R176P results in a type III FD deficiency. 210 
(A) Chromatograms for the DNA sequence adjacent to position c.602 are shown for each 211 
member of the pedigree. The identified variant is rare: the EXAC database reports mutation 212 
R176P (variant 19:861943 G/C) at an allele frequency of 1.049x10-4, with no homozygotes.E9 213 
(B) Western blot analysis of FD in serum from the patient and healthy control. 214 
(C) Secondary structural compositions of WT and R176P FD were evaluated using circular 215 
dichroism spectroscopy.  216 
(D) Comparison of in vitro catalytic activity of recombinant WT, R176P, R176Q and R176A 217 
FD  in terms of FB cleavage. (***, p<.001; ****, p<.0001). 218 
(E) Recombinant WT and R176P FD were tested for the ability to reconstitute alternative 219 
pathway haemolytic activity when added to FD-depleted serum.  220 
 221 
Figure E2: Mutation R176P stabilises the self-inhibited state of FD. 222 
(A) Structure of free FDE3 (PDB ID: 2XW9) showing the catalytic triad (Ser183-His41-223 
Asp89) in an inactive conformation stabilised by the self-inhibitory loop 199-202 (red) and 224 
an ion bridge between Asp177 and Agr202. The exosite loops are shown in yellow. 225 
(B) Structure of C3bB-bound FDE3 (PDB ID: 2XWB) omitting the C3b and FB components. 226 
FD exosite loops retain a conformation similar to that of unbound FD.  227 
(C) WT, R176P and R176A structures were stable over 100 ns of unrestrained molecular 228 
dynamics simulation with explicit solvent. RMSD, root mean square deviation. 229 
(D) Root mean square fluctuation (RMSF) in WT and mutant FD over the second half of the 230 
trajectory. 231 
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(E) Differences in WT versus R176 RMSF mapped to the FD structured. MD predicted 232 
increased mobility in exosite loops, notably 155-167, and decreased mobility in loops 233 
carrying the catalytic His41 and Asp89 residues.  234 
 235 
Fig E3: Assessment of glucose tolerance in patients with functional FD deficiency. 236 
Patient and sibling were given 75g of oral glucose at 0 minutes and blood glucose was 237 
measured at regular intervals between 0 - 120 minutes. The error bars indicate the range of 238 
plasma glucose concentrations between the patient and sibling. 239 
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